Amneal Q2 revenue beats on specialty segment growth

Overview

• US generic drugmaker's Q2 revenue rose 10% yr/yr, beating analyst expectations

• Adjusted EPS for Q2 beat analyst expectations

• Company raised full-year 2026 guidance

Outlook

• Amneal raises 2026 net revenue guidance to $3.10 bln-$3.20 bln from $3.05 bln-$3.15 bln

• Company now sees 2026 adjusted EBITDA of $750 mln-$780 mln, up from $740 mln-$770 mln

• Amneal expects 2026 adjusted diluted EPS of $0.96-$1.06, up from $0.95-$1.05

Result Drivers

• SPECIALTY SEGMENT GROWTH - Specialty net revenue rose 17%, driven by branded products such as CREXONT, BREKIYA autoinjector, and UNITHROID

• GENERIC AND NEW PRODUCT LAUNCHES - Affordable Medicines net revenue increased 13%, supported by strong performance in complex generics and new product launches, including women’s health products

• LOWER INTEREST EXPENSE AND TAX - Higher revenue and gross profit, lower interest expense, and a lower tax provision more than offset increased SGA expense, boosting net income

Company press release: ID:nGNX9T40b3

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the pharmaceuticals peer group is "buy"

• Wall Street's median 12-month price target for Amneal Pharmaceuticals Inc is $19.00, about 0.5% below its July 29 closing price of $19.10

• The stock recently traded at 18 times the next 12-month earnings vs. a P/E of 12 three months ago

Reuters Recommended Reads

• July 29 - Teva Pharm profit misses estimates, seeks US tariff details

• July 29 - Processa buys Vidya Therapeutics, raises $200 million for drug trials

• July 28 - Incyte beats Q2 revenue estimates on strong product demand

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)